Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 11:36 ET | Source: Spherix Global Insights

Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies

Exton, PA, May 28, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the 2026 update of Market Dynamix™: Idiopathic Inflammatory Myopathies (IIM), US, revealing a market increasingly...
March 18, 2026 08:00 ET | Source: Alumis Inc.

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 AAD Meeting
January 06, 2026 16:12 ET | Source: Alumis Inc.

Alumis Announces Proposed Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock
January 06, 2026 07:00 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
November 04, 2025 08:00 ET | Source: Alumis Inc.

Alumis to Participate in Upcoming November Investor Conferences

Alumis to participate in two upcoming November investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conf and the Stifel 2025 Healthcare Conf
October 16, 2025 09:42 ET | Source: Spherix Global Insights

Sjögren’s Disease Remains an Underdiagnosed and Underguided Condition, Creating an Opening for Manufacturers to Shape the Future of Care, According to Spherix Global Insights

EXTON, PA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Sjögren’s Disease (SjD) continues to present significant diagnostic and therapeutic challenges within rheumatology, according to Spherix Global Insights’...
May 29, 2025 07:55 ET | Source: Alumis Inc.

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
March 25, 2025 02:30 ET | Source: Alumis Inc.

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
March 19, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
March 08, 2025 09:00 ET | Source: Alumis Inc.

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025